STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vivo

翻译毒理学部门（DTT） PAC混合物评估计划（PAC- map）提供了一个框架，用于评估单个多环芳烃化合物（PAC）的范围，定义PAC混合物，以及复杂的含PAC的环境样品，使用体外/短期体内测试电池，包括广泛的端点。选择性pac具有广泛的毒性（致癌性、免疫毒性、生殖和发育毒性、神经毒性）和一系列复杂的作用机制。许多PACs与体液免疫功能的抑制有关，免疫毒性已被确定为估计PACs致癌潜力的信息参数。作为预测混合效应的潜在测试电池的一部分，我们研究了13个单独的pac和3个混合物调节抗原特异性抗体反应和影响骨髓细胞学的潜力。23财年没有启动体内免疫毒理学研究，工作重点是报告/存档前合同年度进行的研究。BRT为PAC混合物提供了2份最终报告，完成了这些研究的报告。BRT完成了另外3份关于紫锥菊和双酚F免疫毒性研究的报告草案，最终报告将在合同第10年完成。此外，BRT还参与了6篇论文的领导、数据分析和写作，其中3篇论文在23财年被录用发表。两份手稿正在美国国立卫生研究院的审批过程中，PAC-MAP研究的几篇论文正在准备中。

The Division of Translation Toxicology (DTT) PAC Mixtures Assessment Program (PAC-MAP) provides the framework for assessing a breadth of individual polycyclic aromatic compounds (PACs), defined PAC mixtures, and complex PAC-containing environmental samples using an in vitro/short-term in vivo testing battery that includes a broad spectrum of endpoints. Select PACs have been associated with a wide range of toxicities (carcinogenicity, immunotoxicity, reproductive and developmental toxicity, neurotoxicity) and a complicated array of mechanisms of action. Many PACs have been associated with suppression of humoral immune function and immunotoxicity has been identified as an informative parameter for estimating the carcinogenic potential of PACs. As part of the potential testing battery to predict mixture effects, we have examined the potential for 13 individual PACs and 3 mixtures to modulate the antigen specific antibody response and affect bone marrow cytology. No in vivo immunotoxicology studies were started in FY23 and efforts were focused on reporting/archiving of studies conducted in previous contract years. BRT provided 2 final reports for PAC Mixtures completing the reporting of those studies. BRT completed an additional 3 draft reports for studies of the Immunotoxicity of Echinacea and Bisphenol F with final reports to be completed in contract year 10. In addition, BRT contributed leadership, data analysis and writing for 6 manuscripts, 3 of which were accepted for publication in FY23. Two manuscripts are in the NIH clearance process and several papers from the PAC-MAP studies are in preparation.